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Abstract
The understanding of pathological processes is based on the comparison between physiological and pathological
conditions, and transcriptomic analysis has been extensively applied to various diseases for this purpose. However, the way
in which the transcriptomic data of pathological cells relate to the transcriptomes of normal cellular counterparts has not
been fully explored, and may provide new and unbiased insights into the mechanisms of these diseases. To achieve this, it is
necessary to develop a method to simultaneously analyse components across different levels, namely genes, normal cells,
and diseases. Here we propose a multidimensional method that visualises the cross-level relationships between these
components at three different levels based on transcriptomic data of physiological and pathological processes, by adapting
Canonical Correspondence Analysis, which was developed in ecology and sociology, to microarray data (CCA on Microarray
data, CCAM). Using CCAM, we have analysed transcriptomes of haematological disorders and those of normal
haematopoietic cell differentiation. First, by analysing leukaemia data, CCAM successfully visualised known relationships
between leukaemia subtypes and cellular differentiation, and their characteristic genes, which confirmed the relevance of
CCAM. Next, by analysing transcriptomes of myelodysplastic syndromes (MDS), we have shown that CCAM was effective in
both generating and testing hypotheses. CCAM showed that among MDS patients, high-risk patients had transcriptomes
that were more similar to those of both haematopoietic stem cells (HSC) and megakaryocyte-erythroid progenitors (MEP)
than low-risk patients, and provided a prognostic model. Collectively, CCAM reveals hidden relationships between
pathological and physiological processes and gene expression, providing meaningful clinical insights into haematological
diseases, and these could not be revealed by other univariate and multivariate methods. Furthermore, CCAM was effective
in identifying candidate genes that are correlated with cellular phenotypes of interest. We expect that CCAM will benefit a
wide range of medical fields.
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Introduction
In order to fully understand pathological processes in clinical
settings at the genomic level, it is necessary to compare the
transcriptomes of pathological processes in individual patients with
those of the physiological processes of normal counterparts.
Although transcriptomic analysis has been extensively applied to
various diseases, the way in which the transcriptomic data of
pathological cells relate to the transcriptomes of normal cellular
counterparts has not been fully explored, and may provide new
and unbiased insights into the mechanisms of these diseases. To
achieve this, it is necessary to develop a method to simultaneously
analyse components across different levels, namely genes and
physiological and pathological processes (e.g. normal and abnor-
mal cellular phenotypes). It is anticipated, if successful, this
approach will reveal hidden relationships between pathogenesis,
developmental mechanisms, and gene regulation.
Gene signature has been a most commonly employed approach
to address this type of problem. A number of methods have been
proposed to measure the degree of inclination towards a certain
signature in individual disease samples: correlation coefficient to
the average gene expression of the signature genes [1,2]; the
median fold change [3]; the (weighted) sum of the expression levels
of signature genes [4,5]. Sandberg et al developed a method using
Singular Value Decomposition (SVD) to measure the similarities
between cancer subtypes and cell lines [6], providing univariate
scores for individual cell lines. Although these approaches are easy
to deal with and can be understood intuitively, there is a pitfall
when they are applied to compare disease and normal cellular
phenotypes: it cannot be assumed that the two cell signatures to be
analysed are independent from each other. For example lymphoid
and myeloid signatures cannot be equally compared and therefore
the analysed results of these gene signature scores should not be
plotted on the same plot, as the relationship between these two
signatures is unknown. This fundamental problem complicates
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comparisons between multiple gene expression signatures of
different haematopoietic cell populations. Considering that hae-
matopoietic cells are classified into tens of different populations by
cell lineage and developmental stage, and that each cell population
is closely related to others [7], those existing methods are
apparently insufficient for obtaining an integral view. Therefore,
multidimensional analysis is required to effectively address this
problem.
Among multidimensional analysis methods, principal compo-
nent analysis (PCA) is most commonly used to analyse the
relationships between samples, although PCA is vulnerable to the
addition of subtle phenotypes and aberrant samples, and is more
suitable for visualising data structure [8,9]. In addition, although it
may be more straightforward to estimate the identity of cells by
directly comparing their transcriptomes with other microarray
datasets using multivariate analysis, for example using Multidi-
mensional Scaling [10,11], this is often not successful because large
between-experimental variations can easily dominate relatively
small differences in gene modification between experimental and
control groups even with meta-analysis methods. Considering that
the variations between malignant cells and normal cells are
generally much bigger than between-group variations of different
normal cell phenotypes, as often seen in the analysis using
hierarchical clustering [12], a new multidimensional approach is
required to make a direct comparison of malignant cell phenotypes
and their corresponding normal counterparts.
Thus, in order to reveal the cross-level relationships between
diseases, genes, and normal cells, we have adapted a multidimen-
sional approach, Canonical Correspondence Analysis (CCA), to
microarray data. Currently, CCA is widely used in ecology and
social science, as it can simultaneously analyse two totally different
types of data – one as response data and another as explanatory data,
revealing the relationships between these two data [9]. CCA is a
variant ofCorrespondenceAnalysis (CA), which has previously been
employed to analyse a single microarray dataset, visualising the
associations between samples (arrays) and genes in single datasets
[13,14]. Baty et al reported a method using a variant of CCA for the
analysis of microarray expression data with respect to binary
response data [15]. As far as we know, the present study is the first to
adapt CCA so as to simultaneously analyse two microarray data,
which is designated as CCA on Microarray data (CCAM).
In order to examine the validity and efficiency of our method,
we have analysed two haematological disorders: leukaemias and
myelodysplastic syndromes (MDS). Table 1 is the summary of
microarray datasets used in this study.
Haematological disorders are classified and understood by
referring to normal haematopoietic cell differentiation. Leukae-
mias are classified on the basis of the cell type involved and the
state of maturity of the leukaemic cells, and categorized into major
four groups: acute lymphoblastic leukaemia (ALL), acute myeloid
leukaemia (AML), chronic lymphocytic leukaemia (CLL), and
chronic myelogenous leukaemia (CML) [16]. The classification of
leukaemias has been further developed by assigning leukaemic
cells to normal haematopoietic cell counterparts based on
morphology, cytochemistry, immunophenotype, genetics and
clinical features, so as to define clinically significant disease entities
[17,18]. This framework is based on the well-known hypothesis
that the genetic lesions of leukaemia result in a block of
differentiation (maturation arrest) that allows leukaemic cells to
continue to proliferate and/or prevents the terminal differentiation
and apoptosis seen in normal white blood cells [19].
MDS are a group of clonal haematopoetic disorders marked by
ineffective haematopoiesis, peripheral cytopenias, and an in-
creased risk of transformation to AML [20]. MDS have been
classified into subgroups, and individual patients are scored, in
order to predict prognosis, especially for assessing the risk of
leukaemic transformation. The International Prognostic Score
System (IPSS) for MDS is composed of three factors: blasts in bone
marrow (BM), karyotype, and cytopenia, and higher scores are
associated with poorer prognosis [21]. The World Health
Organization (WHO) classification of MDS is based on morpho-
logic evaluation of bone marrow cells and genetic abnormalities,
and classifies MDS into 6 major subtypes: refractory anaemia (RA,
or Refractory cytopenia with unilineage dysplasia (RCUD)),
refractory anaemia with ring sideroblasts (RARS), and refractory
cytopenia with multi-lineage dysplasia (RCMD), and 5q-syndrome
(MDS associated with isolated del(5q)), and refractory anaemia
with excess blasts (RAEB-1 [blasts v5%] and RAEB-2 [5{19%
blasts]) [22,23]. Blast percentage of more than 20% is defined as
AML, and reasonably, RCMD and RA show better prognosis with
longer leukaemia-free survival than RAEB-1 and RAEB-2 [24,25].
Genome-wide gene expression analysis (transcriptomic analysis)
has been extensively used for improved understanding of the
diagnosis, prognosis, and pathogenesis of these haematological
diseases [22,26]. In these transcriptomic studies, gene expression
signature (or, gene expression profiles [GEP]) has been most
commonly used to classify haematologic diseases and predict
prognosis [26]. Gene expression signature is typically composed of
tens to hundreds of genes, so that all these genes stably contribute
to classify samples in cross-institutional settings [4,27]. Hierarchi-
cal clustering is most often employed in analyses using gene
expression signatures to classify samples into disease subtypes [28].
Results
Analysis 1: Leukaemia
Based on the assumption that leukaemia is classified by referring
to normal haematopoietic cell differentiation, we attempted to
Table 1. Summary of microarray datasets used in this study.
ID Study design #samples
Microarray
platform Ref
GSE2779 Purified CD34+ progenitor cells from normal karyotype, low blast count
MDS patients,age-matched controls and patients with non-MDS anaemia
28 HG-U133A [49]
GSE13159 BM or blood samples of acute and chronic leukaemia patients 2096 HG-U133 plus 2 [29]
GSE15061 BM samples from MDS and non-leukaemia;
AML data were not used in this study
233 HG-U133 plus 2 [22]
GSE24759 Flow-sorted 38 haematopoietic cell populations;
Pooled samples from 4 to 7 independent donors
211 U133AAofAv2 [30]
doi:10.1371/journal.pone.0053544.t001
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analyse using transcriptomic data the relationships between
leukaemia disease samples and normal haematopoietic lineage
cells. We aimed in this analysis to determine the transcriptomic
identities of individual leukaemia patients by analysing a
transcriptomic dataset of leukaemia (GSE13159 [29]) and that of
haematopoietic cell differentiation (GSE24759 [30]). As this is the
first exemplary analysis using a univariate approach by gene
signature, we also show why we need to introduce a multidimen-
sional method. In the subsequent section, we demonstrate how
CCAM is applied to microarray datasets, and examine the validity
of the method by addressing haematologically well-known
relationships between pathological and physiological processes.
A univariate approach using gene expression
signature. First, we employed a univariate approach to address
this problem, using provisional gene signatures of haematopoietic
cell populations (see Methods). Here, we aim to score individual
disease samples by the degree of maturation into each cell
population. Given that some haematopoietic cell populations may
be too similar to each other to provide meaningful results that
discriminate disease samples, hierarchical clustering was used to
cluster haematopoietic cell gene signatures based on their correla-
tions to individual disease samples (Fig. S1). Based on this clustering,
we chose four distinct (classified in different groups) gene signatures
from relatively immature cells (proxy to haematopoietic stem cells
[HSC]): granulocyte-monocyte progenitor (GMP; CD34z
CD34zCD38zCD45RAz), neutrophilic metamyelocyte (NM;
CD34{SSChiCD45zCD11bzCD16{), immature B cells (Pro-B;
CD34{CD10zCD19z) and mature B cells (Mat-B; mature B cells
with class switched; CD19zIgD{CD27z) [30]. We analysed the
distribution of gene signature scores of disease samples for these cell
populations. As shown in Fig. S2, CLL showed high correlations
with the signature of Mat-B (Fig. S2a), while CML and AML
showed higher correlations with those of NM and GMP (Fig. S2b
and S2c). Generally, ALL showed higher correlations with the
signature of Pro-B (Fig. S2d). These results seemed haematologi-
cally appropriate, considering the immunophenotype of these
leukaemia subtypes [31–34]. It was, however, unclear how these
four results in Fig. S2 were related.
Cross-level relationships between leukaemia subtypes,
haematopoietic cell differentiation, and genes by
CCAM. The results above indicated that it was necessary to
simultaneously analyse components at three different levels: genes,
normal haematopoietic cells, and individual disease samples. To
achieve this, we have developed a new multidimensional and
canonical analysis of two microarray datasets by adapting
Canonical Correspondence Analysis, which was developed in
ecology and sociology, to microarray analysis (we designate the
method as CCA on Microarray data, CCAM) (see Methods, Fig. 1a).
Briefly, in our application of CCAM, pathological data (disease
data) are treated as response data, and physiological data (normal
haematopoietic cell differentiation) are used as explanatory
variables (environmental variables), and thereby we aim to reveal
the relationships between gene expression and pathological and
physiological processes. Assuming that leukaemias are classified by
referring to normal haematopoietic cell differentiation, CCAM is
expected to assign individual disease samples to most correlated
normal counterparts. We used the four representative haemato-
poietic lineage cells that were analysed in the gene signature
approach in Fig. S2 (GMP, NM, Pro-B, and Mat-B).
We have employed a map approach in our method in order to
avoid the pitfalls of simultaneously analysing the complex
relationships between components at three different levels [9].
CCAM provides a map that shows the correlations between genes,
normal haematopoietic cells, and disease samples. In other words,
the more correlated, the nearer components are positioned on the
map [9]. Fig. 1b shows all the components that were analysed at
all the levels (gene, normal cell, and disease). On the map, CLL
showed high correlations with Mat-B, and not with Pro-B and
myeloid cells, compatible with the fact that the phenotype of CLL
is similar to antigen-experienced B cells rather than immature B
cells [31,34] (Fig. 1b and 1c). Although the number of samples is
small, mature B cell-ALL (mature B-ALL) showed a clear
correlation with CLL and Mat-B [33] (Fig. 1d), which is also a
reasonable result. On the other hand, ALL (excluding T cell-ALL
[T-ALL] and mature B-ALL) showed higher correlations with the
signature of Pro-B, which is consistent with the immunophenotype
of non T cell, immature B cell ALL [32,33]. CML and AML
showed higher correlations with the signatures of NM and GMP,
and comparing with AML, CML was more distinct from
lymphocytic leukaemias (ALL and CLL) and deviated more to
the direction to which NM and GMP were correlated (Fig. 1b–1e),
confirming a more differentiated granulocytic phenotype of CML
than AML. T-ALL was distinct from other ALL, and positioned
between B-ALL and AML (Fig. 1d–1e).
By analysing CCA triplot at the gene level, B cell- and B-
leukaemia-related genes have high (positive) scores in axis 1, while
genes related to myeloid cell differentiation and myeloid leukaemia
have low (negative) scores (Fig. 1b). Myeloid genes such as MMP8
and CD33 are in quadrant I (Axis1loAxis2hi ), which is correlated
with myeloid lineage NM and GMP. Genes related to nave or
immature B cell (e.g. POU2AF1, CD19, ID3, VPREB3, RAG1) are
apparently enriched in quadrant III (Axis1hiAxis2lo), which is
correlated with Pro-B. Genes related to mature, antigen-experi-
enced B cells (e.g. CD40, CD86) are found in quadrant II
(Axis1hiAxis2hi), which is correlated with Mat-B. The associations
of components at the three different levels could be observed in
this analysis. For example, in quadrant II, CCL and mature B cells
are correlated with FCER2 (CD23, FcReII), CD180 (RP105), and
CXCR5 (Fig. 1b). In fact, increased expression of these genes is
characteristic in CLL and also associated with maturation of B
cells [35–39]. Interestingly, quadrant IV (Axis1loAxis2lo), which is
not annotated by haematopoietic cells but correlated with AML
and T-ALL, includes RUNX1, ERG, and MYB, which have well-
established roles in AML and early haematopoietic differentiation
including myeloid and T-lymphocyte lineages [40–43] (Fig. 1b).
Thus, the map analysis in Fig. 1 can be summarised as follows:
Axis 1 represents‘‘myeloid cells vs. B lymphocyte’’, while Axis 2
represents ‘‘immature vs. mature cells’’. Individual leukaemia
samples and gene expression were successfully characterised on
this map. The analysis of variation (precisely, inertia [9]; see
Methods) showed that Axis 1, 2, and 3 comprised 68%, 17%, 11%
of variations, respectively. This means that the leukaemia data that
was interpretable by the haematopoietic cell data was mostly
visualised (85% and 97% of the information in the constrained
data in Fig. 1d and 1e, respectively), and that the difference
between myeloid and lymphocytic lineages dominated that of the
maturity of cells in this dataset.
Next, we further analysed the phenotypes of AML subtypes by
CCAM (Fig. S3). We included in the analysis the cell populations
of the myeloid lineage that are relevant in AML, namely,
Common myeloid progenitor (CMP), Colony forming unit-
monocyte (CFU-M), Neutrophilic metamyelocyte, and mature
Neutrophils. CCAM classified AML subtypes with the features of
the granulocytic and monocytic lineages (Fig. S3). CCAM showed
that the subtypes AML with 11q23/MLL and AML with inv(16)/
t(16;16) were more associated with CFU-Monocyte than other
granulocyte lineage cells, which is consistent with the facts that
these subtypes are morphologically more correlated with the
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monocytic lineage [44,45]: a study showed that a majority (81%)
of AML with 11q23/MLL showed an involvement of the
monocytic lineage [44]; AML with inv(16)/t(16;16) has the fusion
gene CBFb/MYH11, and is morphologically associated with the
French-American-British (FAB) AML-M4 subtype (acute myelo-
monocytic leukaemia with an abnormal eosinophil compo-
nent)[45]. In addition, CCAM showed that the subtypes AML
with t(15;17) and AML with t(8;21) were more related to
Neutrophil, which is consistent with their morphological associ-
ations with the granulocytic lineage: AML with t(15;17) has the
PML-RARA fusion gene and corresponds to the FAB M3 subtype
(acute promyeolocytic leukaemia) [46,47]; AML with t(8;21) has
the fusion gene AML1(RUNX1)/ETO and corresponds to the
AML-M2 (acute myeloid leukaemia with maturation) [48]. See
File S1 and Fig. S4 for the further analysis of these two datasets.
Analysis 2: Myelodysplastic Syndromes (MDS)
The analyses above showed that CCAM successfully revealed
known relationships between leukaemia, haematopoietic cell
differentiation, and genes in a concise and transparent way. In this
section, we examined whether the approach was effective in
generating and testing hypotheses, and questioned whether this
method could provide meaningful insights into clinical problems.
Accordingly, we analysed two independent MDS datasets. The first
analysis was carried out in order to generate a new hypothesis. We
then tested the hypothesis by analysis of another independent
dataset.
Analysis for hypothesis-generation: comparison of MDS
and normal bone marrow (BM). We analysed the transcrip-
tomic data by Sternberg et al (GSE2779 [49]) along with that of
haematopoietic cell differentiation (GSE24759). Sternberg et al
showed that CD34z progenitor cells from normal-karyotype, low-
blast-count MDS patients consistently showed decreased expres-
sion of B-cell lineage-affiliated genes [49]. We attempted to
confirm this result, while obtaining a bigger picture using not only
the data of immature B cells (Pro-B) but also those of other
progenitors including MEP (megakaryocyte-erythroid progenitor),
GMP, and CMP, and haematopoietic stem cells (HSC). In order
to find the unique features of MDS BM using the relatively small
number of disease samples analysed in this dataset, we filtered
genes using the disease data.
CCA triplot showed that axis 1, which was composed of the
largest variation in the dataset, is primarily represented by the
difference between MDS and normal BM as well as that between
HSC/MEP and CMP/Pro-B. As Sternberg et al reported, MDS
samples had negative correlations with Pro-B (Fig. 2a). In addition,
CCA triplot showed that MDS samples had positive correlations
with HSC and MEP. Although the number of samples is small,
non-MDS anaemia samples were in the middle of MDS and
normal BM in axis1 (Fig. 2b). Interestingly, KIT and NPM1, the
mutations in which are suggested to play roles in leukaemic
transformation [50,51], were correlated with MDS and HSC/
MEP. B cell-related genes including POU2AF1, PAX5, and CD19,
were associated with normal BM as reported [49] (Fig. 2a).
Examination of hypothesis: BMs from high-risk MDS
patients showed the deviation towards HSC/MEP at
transcriptomic level. Based on these findings, we generated
a hypothesis that MDS patients with higher correlations with both
HSC and MEP (and negative correlation with Pro-B) had a higher
risk for leukaemic transformation. To test this hypothesis, we have
applied CCAM to another independent dataset of MDS that is
composed of only MDS patients (without normal), and analysed
the results in conjunction with the clinical data (GSE15061 [22]).
First, using CCAM, we determined the relationships between
individual MDS patients and haematopoietic cells based on their
transcriptomes (Fig. 3a). Next, we superimposed clinical data onto
this plot. Interestingly, MDS patients with high scores in IPSS
scores (cytopenia, and blast) had higher values in axis1 compared
with those with low scores (pv0:001 for cytopenia [cytopenia
score w0:5 vs. 0], pv0:05 or pv0:001 for blast [blast v5% vs.
blastw5% or 11%, respectively], Fig. 3b). IPSS category itself had
a similar tendency: individuals with IPSS w1:5 had significantly
higher scores in axis 1 (pv0:01). According to the WHO
classification, RAEB-2 had significantly higher axis 1 scores than
others (pv0:05). Importantly, principal component analysis (PCA)
could not reveal these characteristics of MDS patients (Fig. S5),
demonstrating the value of CCAM.
CCAM created a new scoring system that has a prognostic
value and biological relevance in haematopoietic cell
development. The results in Fig. 3 suggest that a positive
association with HSC/MEP and a negative association with CMP
has a prognostic value. Thus, using top ranked genes (top 100 and
bottom 100 genes by the wa score of CCAM, see Method), we
analysed the relationships between individual patients and their
associations with the four haematopoietic cell populations, and
thereby established a scoring system forMDSpatients (designated as
the HSC-CMP score). As expected, genes with high HSC-CMP scores
were specific to HSC/MEP, while those with low scores were
specific to CMP/GMP (Fig. S6). MDS patients were stratified into
two or three groups by the HSC-CMP score, and two to four groups
by well-established prognostic scores and the disease categories in
the WHO classification. Kaplan-Meier survival analysis showed
that the HSC-CMP score had prognostic values for overall survival:
patients with scores above the 50th percentile showedworse survival
(Fig. 4a pv0:02) and those above the 95th percentile had the worst
prognosis by log-rank test (Fig. 4b pv2|10{4).While the IPSS and
cytopenia scores showed p-values just above the significant
level(p~0:054 and p~0:055, respectively), disease categories
showed significant difference between patient groups (Fig. 4g,
pv0:002). Similarly, Kaplan-Meier survival analysis for time to
Figure 1. CCAM of transcriptomic data of leukaemias with haematopoietic cell differentiation as explanatory variables. Leukaemia
data were analysed with those of haematopoietic cell populations at distinct differentiation states (Granulocyte-monocyte progenitor [GMP],
Neutrophilic metamyelocyte, Pro-B cell, and Mature B cell class switched,). (a) Schematic presentation of CCAM. Transcriptomic datasets of leukaemias
(including AML, CML, ALL, and CLL) and haematopoietic cells were processed by CCA and the cross-level relationships between components at three
different levels, namely disease, cell, and gene, were analysed. (b) All three levels are shown on a map (CCA triplot). Centroids of disease samples are
shown by large closed circles, and 95% confident intervals (CI) are indicated by ellipsoids. Genes are shown by closed grey circles, and well-known
genes that are key for either leukaemia or haematopoietic cell differentiation are annotated. Haematopoietic cells are represented by blue arrows,
towards which genes and diseases that are closely related to the corresponding cell are aggregated. (c, d) The levels of disease and cell are shown. (c)
Individual disease samples are shown in addition to 95% CI. (d) Two-dimensional plot of disease samples and haematopoietic cell populations. The
amount of information (eigenvalue) retained in each axis is 68% and 18% of the total variation (precisely, constrained inertia, see Methods) for Axis 1
and 2, respectively. (e) Three-dimensional plots of disease samples and haematopoietic cell populations. The amount of information (eigenvalue)
retained in each axis is 68%, 18%, and 11% (of the constrained inertia) for Axis 1, 2, and 3, respectively. See legend for symbols and colours in (d) and
(e).
doi:10.1371/journal.pone.0053544.g001
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AML transformation showed that patients who scored above the
50th percentile had worse prognosis (Fig. 5a, pv0:02), while the
stratification of patients into three groups by the HSC-CMP score
was less significant (Fig. 5b, p~0:054). Regarding the AML
transformation, reasonably, blast score and disease categories
showed the lowest p-values (Fig. 5d and 5g, pv1|10{5 and
pv1|10{4, respectively).
To further address the significance of the HSC-CMP score, we
employed a Cox proportional hazard regression analysis for
overall survival and time to AML transformation. The univariate
Cox analysis showed that the HSC-CMP score and the IPSS score
were significant both for time to AML transformation (pv0:02
and pv0:002, respectively) and for overall survival (pv0:001 and
pv0:05, respectively, Table 2). Cytopenia and Blast scores were
also significant for time to AML transformation (pv0:05 and
pv0:0005, respectively). Next, we performed a multivariate Cox
regression analysis with the IPSS score and the HSC-CMP score
(three stratified groups), which showed that the HSC-CMP score
remained significant for overall survival but the IPSS score did not
(pv0:01, hazard ratio [HR]~2:11; and p~0:90, HR~1:02;
respectively), while the IPSS score remained significant for time to
AML transformation but the HSC-CMP score did not (pv0:05,
hazard ratio [HR]~1:43; and p~0:50, HR~1:78; respectively).
Lastly, we performed a multivariate Cox regression analysis with
the HSC-CMP score, Cytopenia score, Blast score, and Karyotype
score. The analysis for time to AML transformation did not show
any statistically significant results except that Blast score was
significant (pv0:01,HR~2:52). The analysis for overall survival
showed that the HSC-CMP score had the largest impact
(pv0:005, HR~2:29), and other scores failed to show significance
(Table 2). These results suggest that although the HSC-CMP score
was not independent from the IPSS and other scores, it was a
dominant prognostic factor for overall survival.
Discussion
CCAM has provided novel insights into the cross-level
relationships between gene expression and pathological and
physiological processes, which could not be obtained by the
analysis at each single level. Importantly, many medical problems
require the analysis of disease samples in the context of some
particular biological processes (e.g. cell differentiation), which are
most often multidimensional in nature and are often not
straightforward. CCAM has effectively solved this type of
problems by analysing two independent transcriptomic data.
Visualisation of the analysed results has made it transparent which
cell populations are being compared for the relationship with
disease samples. In addition, CCAM allows the exploration of
novel molecular mechanisms that are highly associated with
particular cell and/or disease. For example, in Fig. 1, CCAM has
identified known genes that had roles in haematopoietic cell
differentiation and leukaemia. This result suggested that other
genes that are associated with (in juxtaposition to) these known
genes and with particular diseases and cells are reasonably good
candidates for undefined molecular mechanisms of these diseases
and cells, considering the nature of the underlying algorithm,
Correspondence Analysis [9,14]. Thus, CCAM with the map
approach is useful for generating hypotheses with least assump-
tions, and is expected to lead to hypothesis-driven studies. In
addition, we used CCAM effectively to test a hypothesis on the
transcriptomic characteristics of MDS patients. Furthermore, the
proposed approach can identify individuals with worse clinical
outcomes, and infer the mechanisms underlying poor prognosis, as
shown by the analysis of MDS. The clinical utility of this approach
is thus demonstrated.
New biological insights from CCAM: the positive
correlation of transcriptomes of high risk MDS patients
and those of HSC/MEP (and the negative correlation of
MDS with CMP)
Consistent with a previous report [49], MDS samples showed
decreased or negative correlations with the process of early B cell
differentiation compared with healthy controls. In adddition, our
analysis has revealed that MDS samples are more correlated with
the processes of both HSC maintenance and MEP differentiation.
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Figure 2. CCAM of MDS transcriptomic data of CD34z cells from MDS, non-MDS anaemia, and normal BM, analysed
together with those of haematopoietic cell differentiation.Microarray data of CD34z cells from MDS, non-MDS anaemia, and healthy
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Interestingly, while the process of early B cell differentiation did
not show correlation with the severe phenotype of MDS, the
transcriptomic statuses of HSC and MEP showed remarkable
correlations with it (Fig. 3). The leukaemic transition of MDS is
widely known to be associated with the immaturity (the acquisition
of stem-ness [HSC]) [22,23], while the association between MDS
and MEP (in comparison with myeloid/lymphoid differentiation)
has not been recognised. This is the power of the new approach: to
simultaneously and fairly consider multiple phenotypes, providing
an integral view on the system.
As RNA for hybridization was extracted from unsorted,
mononuclear BM cells from MDS patients in this dataset
(GSE15061) [22], the result should be interpreted considering
possible compensatory mechanisms in BM by non-MDS cells. It is
noticed, however, that another dataset, GSE2779, analysed
purified CD34z progenitor cells, resulting in a similar conclusion.
In addition, our results showed that RARS BM, which charac-
teristically show hyperplastic ineffective erythropoiesis [52], did
not have positive correlations with MEP and HSC, and that 5q-
syndrome, which typically shows normal to increased megakar-
yocytes [23], did not show positive correlations with MEP. Rather,
5q-syndrome and RARS showed lower values in Axis 1, and were
more correlated with CMP (Fig. 3f). Given that the largest
variation can be observed in axis 1 of CCAM results, these results
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indicate that the distinct feature of BM from severe MDS patients
dominated the variations in MDS including those compensatory
mechanism and secondary responses. Interestingly, a recent report
showed that decreased expression of erythroid-specific genes was
correlated with the responsiveness to the thalidomide derivative
lenalidomide in patients with 5q-syndrome, which is the most
homogenous subtype of MDS [53]. Our results, along with the
results of this study, suggest that MDS with higher correlations
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with the erythroid lineage (and HSC) are more difficult to treat
with lenalidomide.
Importantly, the HSC-CMP score showed a prognostic value
for overall survival (Fig. 4–5 and Table 2). Given that the HSC-
CMP score was correlated with the characteristic gene expression
in HSC/MEP and CMP/GMP (Table S1 and Fig. S6), those
genes can be investigated to elucidate the molecular mechanisms
of MDS pathogenesis in relation to the cellular and differentiation
processes of these haematopoietic cell populations. These findings
above suggests that disease progression in MDS is accelerated by
the aberrant utilisation of the molecular mechanisms of erythroid/
megakaryocyte (MEP) differentiation and stemness (HSC) and the
loss of the mechanisms of CMP and/or GMP. The investigation of
these processes may provide clues to identify new therapeutic
targets that improve overall survival. Thus, CCAM provides
biologically effective and meaningful solutions because it analyses
simultaneously and cohesively two different phenotypic levels -in
this case, MDS pathology and normal haematopoietic cell
development.
Our analyses using transcriptomic data obtained from batch
samples have revealed the transcriptomic identities of the
phenotype of dominant cells or ‘average’ cells in the context of
normal haematopoietic cell differentiation. It is known that
variations can occur within individual cancers, in which the
cancer cells often have a range of functional properties and diverse
expression of markers [54]. In addition, it is thought that
leukaemia has a hierarchical organization similar to that of
normal haematopoiesis in which there is a rare subpopulation with
limitless self-renewal potential (leukaemic stem cells) that gives rise
to progeny that lack such potential [55]. Considering this, in
conjunction with the use of our method, gene expression analysis
at the single cell level will be the key to reveal further relationships
between normal cells, cells of origin, and leukaemia stem cells.
CCAM provides the framework to analyse this type of data.
Technical considerations on the use of CCAM
CCAM does not produce ready-to-go results, but provides a
platform where the existing hypotheses are examined and new
hypotheses are formed and generated. Depending on how
explanatory variables are set and used, CCAM can be used for
exploratory purposes in a data-oriented way (c.f. Fig. 1) or for
examining the original hypothesis (c.f. Fig. 3). The map approach
enables the comparisons of more than two variables, while the
regression process in CCAM allows the analysis across two
different experiments. These are advantages of CCAM but can
mislead the analysis if inappropriately used. The users should be
aware of the following two points. First, because the underlying
algorythm, CCA, uses multiple regression, one needs to avoid the
pitfalls of multiple regression when choosing explanatory variables:
the number of explanatory variables should be less that that of
samples, in order not to overfit the data to explanatory variables;
and the interpretability of the results is directly dependent on the
choice and quality of the explanatory variables [56]. Second, when
the final result of CCAM has only a very small part of the original
‘‘information’’ (i.e. %Explained is very low [e.g. v5%], see
Methods), interpretation should be cautious. Although the
absolute value of %Explained does not reflect the biological
relevance, if %Explained is comparable between analyses (see
Methods), the results with larger %Explained values may be
biologically more reasonable and straightforward.
Importantly, the effective use of CCAM requires deep
knowledge of both biology/medical science and multidimensional
analysis. Because CCAM can help the process of hypothesis
generation and testing, this method is best performed when
biologists/medical scientists actively participate in the analysis.
Readers with biological backgrounds are encouraged to under-
stand the procedures of CCAM in Fig. 6, and those with
bioinformatics/statistical knowledge can refer Fig. S7 for the
theoretical background of CCAM, and use an R script of CCAM
in File S1. If successfully applied, CCAM will allow one to address
more complex questions which could not be done by conventional
Table 2. Results of the univariate and multivariate Cox proportional hazard regression analysis.
Time to AML transformation Overall survival
Covariate P Hazard ratio Confidence interval P Hazard ratio Confidence interval
Univariate hazard ratios
HSC-CMP score ,.02* 2.57* 1.17–5.64 ,.001* 2.15* 1.37–3.38
IPSS score ,.002* 1.99 1.29–3.06 .03* 1.34 1.03–1.74
Cytopenia score ,.05* 2.92* 1.15–7.41 .059 1.66 0.98–2.80
Blast score ,.0005* 2.85* 1.64–4.97 .27 1.21 0.86–1.70
Karyotype score .08 1.84 0.93–3.62 .061 1.49 1.00–2.26
Multivariate hazard ratios
HSC-CMP score .50 1.43 0.51–4.03 ,.01* 2.11* 1.20–3.71
IPSS score ,.05* 1.78 1.03–3.07 .90 1.02 0.72–1.45
Multivariate hazard ratios
HSC-CMP score .86 1.10 0.37–3.26 ,.005* 2.30* 1.29–4.10
Cytopenia score .89 0.91 0.24–3.40 .84 1.08 0.54–2.16
Blast score .01* 2.82* 1.27–6.27 .28 0.79 0.51–1.22
Karyotype score .92 1.04 0.50–2.18 .33 1.25 0.79–1.98
HSC-CMP score is the score made by CCAM, and stratified patients into three groups (w95%, 95{50%, and v50%). Cytopenia, Blast, and Karyotype scores are the
scores that constitute the IPSS score. These scores were examined for their impacts on overall survival and time to AML transformation.
Pv0.05 or hazard ratio w2.0.
doi:10.1371/journal.pone.0053544.t002
Visualisation of Normal and Disease Transcriptomes
PLOS ONE | www.plosone.org 9 January 2013 | Volume 8 | Issue 1 | e53544
methodologies. The use of CCAM and related multidimensional
methods will extend the power of experimental technologies, as it
has benefited the field of ecology [56,57]. Table 3 summarises the
features of CCAM in comparison with univariate approaches
including gene signature and multivariate/multidimensional ap-
proaches including PCA and CA.
Notably, CCAM has clarified in the analysis exactly what is
compared and analysed, with the power of the map approach.
Although it might be obvious to haematologists that HSC is
correlated with the progression of MDS, CCAM revealed this
without prior knowledge, and more importantly, showed that this
statement was true only when patient samples were compared with
not only HSC but also some more differentiated cells. CCAM
identified that CMP was an appropriate cell population to be
compared with HSC (c.f. Fig. 3). In addition, CCAM showed that
MEP was correlated with MDS patients with worse prognosis at
an equivalent level to HSC (Fig. 2–3). These led to the
establishment of the HSC-CMP score, which had a prognostic
value and biological relevance in haematopoietic cell development
(Fig. 4–5, Table 2, Table S1). Such a complicated comparison of
multiple phenotypes is important for a deep understanding of the
system, but this is generally difficult by conventional approaches.
The power of CCAM lies in its ability to deal with multiple
phenotypic data based on quantitative measurements (i.e. gene
expression).
Conclusions
CCAM provides a practical solution for comparing multiple
groups of samples with multiple cellular phenotypes. In addition,
CCAM reveals hidden relationships between pathological and
physiological processes and gene expression, providing novel
clinical insights into haematological diseases. In fact, CCAM
provided new insights such as the correlation of the severe
phenotype of MDS and MEP, in addition to the known
correlation with HSC. Furthermore, CCAM can be effectively
used for exploring the genes that are correlated with cellular
phenotypes of interest using the map approach (c.f. Fig. 1).
The strength of CCAM is its ability to explore datasets for
hypotheses-generation using the map approach. Once a hypoth-
esis is generated, we can test the hypothesis by this method using
other datasets (c.f. Fig. 3) or by other methods such as statistical
comparison of a few selected groups. The map-based approach is
popular in social science and ecology [9], because in these research
fields it is mandatory to analyse the relationships between many
different, but closely associated qualitative data (e.g. different
human attitudes [9,58], species, and the analysis without
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visualisation can be misleading [9,59]). In fact, qualitative data
(e.g. disease classification, cell subtype) are becoming more and
more complex in modern medicine with the emergence of
genomics, and we believe that this type of approach is essential
and should be incorporated into medical genomics. In addition,
considering the generality of the method, the proposed approach
can be applied to common problems in broad fields of molecular
biology.
Materials and Methods
Canonical Correspondence Analysis on Microarray data
(CCAM)
Conceptual definition of CCAM. CCA is a variant of
Correspondence Analysis (CA), which is a key method in
sociology, and is developed in ecology for identifying the
relationships between ecological data at three different levels
[9,59]. We have chosen CCA because it can analyse the rows and
columns of two transcriptomic data that are derived from two
independent experiments with totally different experimental
designs and materials. When these data are analysed by
conventional approaches, the distance between different experi-
ments (between-experiment variations) dominates important
biological effects in the datasets, and compromises the direct
comparison of leukaemic cells and normal haematopoietic cells.
On the other hand, CCA looks at the intersection of the two
completely different datasets (but obtained for the same genes) and
thus avoids this problem. CCA in our method analyses the
relationships between genes and disease samples in the context of
haematopoietic cell differentiation (corresponding to geological
locations, species, and environmental variables, respectively, by ter Braak
[59]; gene expression levels correspond to frequencies). Note that
in CCAM, CCA is applied to a matrix of data with genes in rows
(observations, equivalent to geological locations by ter Braak) and
cellular phenotypes in columns (variables, equivalent to species and
environmental variables by ter Braak).
Briefly, first, CCAM projects the dataset of disease samples onto
the data of haematopoietic cell differentiation, which are averaged
for each cell population using scaled data with an average of zero
and standard deviation of one for each gene (Fig. S7). Importantly,
the gene expression data of haematopoietic cells represent the
environmental variables that define the phenotypes of each cell
population. Thus, CCAM analyses the interpretable part of the
original disease dataset by haematopoietic cell data [9,59]. Mostly
the interpretable part (%Explained, see below) was 10–20% of the
original data in the presented analyses [9]. Next, CCAM finds new
axes by assigning numerical values to samples and genes so that
the dispersion of samples is maximized [59].
Instructions on the practical usage of CCAM. Fig. 6a
depicts how to use CCAM. (1) Prepare datasets. ‘‘Dataset to be
explained’’ will be the data that analysed more ambiguous
materials (e.g. disease samples) and are of most interest in the
analysis. ‘‘Dataset to explain’’ will provide explanatory (environ-
mental) variables, and be the one that analysed well-characterised
materials (e.g. normal cells). (2) Choose genes using ‘‘dataset to
explain’’ by some statistical method (e.g. a moderated t-test).
Besides, prepare explanatory variables from ‘‘Dataset to explain’’
by taking the average for each group. Carefully choose explan-
atory variables by both biologically thinking and statistically
examining: identify and exclude the variables that have high
correlations with others. (3) Perform CCA using ‘‘Dataset to be
explained’’ and explanatory variables. CCA regresses the former
on the latter and thereby identifies the interpretable part of
‘‘Dataset to be explained’’ (designated as ‘‘Constrained data’’).
Subsequently CCA perfomes singular value decomposition of
Constrained data and obtain ‘‘uncorrelated’’ axes (components).
The axes are ordered by variation (eigenvalue), and first axes have
largest eigenvalues. (4) Visualise the result of CCA using the first
axes, and perform map analysis. Use two-dimensional map
analysis before using three-dimensional plot (c.f. Fig. 1). First,
interpret axes using a deep knowledge on the biological system and
the experimental settings, although axes are not always interpret-
able [9]. It is generally helpful to analyse the relationships between
axes and explanatory variables. Second, identify key sample
clusters. Note that correlated elements gather towards the same
direction from the origin. Strictly speaking, the size of the sample
space is different from that of the gene space [9], therefore, do not
use the Euclidean distance to measure the similarities between
elements across different levels (e.g. cell samples and genes), but
use angular distance instead to analyse the relationships between
them. Third, explore key genes that are correlated with key
clusters of samples and explanatory variables. (5) Lastly, design the
next analysis. Optimise the combination of explanatory variables
by performing CCAM using the same genes, and comparing
%Explained of the analyses with different combinations of
variables. It is also important to consider to remove unnecessary
samples and/or genes, which can blunt the important difference
between elements. The outputs of CCAM can be used as a scoring
system.
The analysis of variations in CCAM: decomposition of
inertia
Fig. 6b summarises how the variation in ‘‘Dataset to be
explained’’ is decomposed and retained in the result of CCAM. In
the analysis using CA and CCA, the variation in data is measured
by inertia, which plays the same role as the total variance in PCA.
Technically, inertia is the sum of total Pearson x2 divided by the
Table 3. The features of CCAM and other univariate and multivariate/multidimensional methods for microarray analysis.
Method
Analysis for a single
variable
Simultaneous analysis of
$2 variables
Analysis across 2
different experiments Exploratory analysis
Hypothesis driven
analysis
Univariate1) ! ! !
PCA ! !
CA ! !
CCAM (CCA) ! ! ! ! !
Although the methods can be used for the application without ‘‘ticks’’ in some limited situations, the maximal productivity may be obtained by those with ‘‘ticks’’.
1) Includes various methods for the signature approach. Commonly analysed using clustering methods.
doi:10.1371/journal.pone.0053544.t003
Visualisation of Normal and Disease Transcriptomes
PLOS ONE | www.plosone.org 11 January 2013 | Volume 8 | Issue 1 | e53544
total sum [9]. Total inertia, IT , is decomposed into two parts,
constrained inertia, IC , and unconstrained inertia (IT{IC ).
%Explained~IC=IT defines how much of the information in the
original data is retained at this stage, and is useful for addressing
the relevance of the findings by CCAM in terms of variation. Next,
CCAM performs singular value decomposition, and constrained
inertia is decomposed and distributed into new axes,
IC~a1,a2,a3.... %Visualised is defined as a ratio of (The sum of
eigenvalues in the visualised space)=(Constrained inertia), and is
useful to determine how many dimensions should be used.
%Explained is comparable between the results from different
combinations of explanatory variables, when the same genes are
used and the main data matrix is the same.
Algebraic definition of CCAM. Suppose that the normal-
ised gene expression of reference cell subsets (environmental variables)
is F~½d1,:::,dq[<l|q, and the microarray data Z[<l|p. We
assume that F is standardized using r as weights for rows in the
calculation of means and variances (see the constrained conditions
of g in the previous subsection). CA standardizes Z in the x2-
metric, and subsequently performs singular value decomposition
(SVD) as in the following steps (Fig. S7): (1) Using n, Dr~diag(r)
and Dc~diag(c) (see above), Z can be standardized in the x
2-
metric, S~D
{12
r (
1
n
Z{rcT )D
{12
c . (2) CCA projects S onto D,
while probes are always weighted by the sums of rows of Z. Thus,
the projection matrix is Q~D
1
2
rZ(Z
TDrZ)
{1ZTD
1
2
r, and the
projected (constrained) matrix is S~QS. (3) Calculate the SVD
of S: S~UDaVT where UTU~VTV~I , and Da is the
diagonal matrix of singular values in descending order
(a1§a2§:::). (4) Gene scores are given by D
{12
r UDa, and sample
scores are by D
{1
2
c V . (5) Constrained inertias are
lk~a
2
k(k~1,:::,K), where K~min(l{1,p{1,q). The percentage
of the explained information in the k-th axis is expressed by
%Explained (of constrained inertia)~
a2kP
k a
2
k
. (6) In order to
display environmental variables in triplots, environmental vari-
ables ~dn in F are linearly regressed to each axis of U~(u1,:::,uK ).
Suppose that ~dn(n~1,::,q) is standardized, the standardized
regression coefficient b~cov(~dn,uj)(n~1,::,q; j~1,:::,K), which
is used for displaying environmental variables in triplots. (7) Using
r~(r1,:::,rl) and c~(c1,:::,cp), total inertia of the original gene
expression matrix is w2~
Xl
i~1
ri
Xp
j~1
(
1
n
zij
ri
{cj)
2 1
cj
.
%Explained~
P
k a
2
k
w2
is an estimate of how much of the original
information is retained in the solution.
Microarray data and processing
We have used GSE24759 for haematopoietic cell differentiation
[30], GSE2779 and GSE15061 for MDS data (Table 1) [22,49],
GSE13159 for leukaemia data [29]. Microarray data were
normalised by rma of the Bioconductor package, affy. Cross-
platform comparisons were made by a commonly employed
algorithm [60]. Batch-effects within each dataset, if any, were
adjusted by an established approach using empirical Bayes
methods [61]. Data were further normalised across genes. PCA
was done by the function dudi.pca of the CRAN package ade4.
We used the CRAN package, vegan, for the computation of CCA
[62]. An R script for CCAM is available as File S1. Microarray
data of diseases and those of haematopoietic cell populations
(environmental variables) were seprately normalised, as CCA
analyses the data that were projected onto environmental
variables, and normalisation of data of diseases and environmental
variables did not have impacts on the results of CCA (data not
shown). For sample scores, we employed wa score, and biplot
arrows are based on weighted correlation of sample scores and
haematopoietic cell differentiation [62,63]. Genes were filtered by
the same method used for gene signature, using haematopoietic
cell data only, unless indicated. Thus, these analysis results are
unsupervised for disease samples and do not use clinical
information and sample identities. Sample scores of CCA results
were first analysed by Kruskal-Wallis test for comparisons of
multiple groups. Mann-Whitney U-test was used for the compar-
ison of two groups. P-value was adjusted by the Bonferroni
correction. Three-dimensional plots in Fig. 1e and Fig. S6 were
produced by the R packages, rgl and lattice, respectively.
Provisional gene signatures were identified by a moderated,
empirical Bayes t-statistic implemented in the Bioconductor
package limma [64]. The top ranked genes (n~500) in comparison
with all other cell populations by topTable of limma were designated
as the provisional signature genes of each cellular population.
Gene signature score was derived by analysing the averaged
expression of signature genes and the gene expression of each
disease sample by Pearson’s correlation coefficients. Obtained
scores were further scaled so as to have an average of zero and
standard deviation of one, because the primary interest of the
analysis is to compare between disease samples.
Statistical analysis of survival data
Log-rank test was used for analysing the survival data of the
stratified groups of patients. Cox proportional hazard models were
used for analysis of survival data. The CRAN package, survival, was
used for these computations.
Supporting Information
Figure S1 Hierarchical clustering of gene expression signatures
of haematopoietic cells by correlation to a leukaemia disease
dataset. All the haematopoietic cell populations in GSE24759
were analysed. A gene signature was identified for each
haematopoietic cell population, and gene signature score was
calculated as a correlation between each signature and individual
leukaemia sample, and shown by a heatmap. Yellow indicates
positive correlation, and red indicates negative ones. Identified
clusters of haematopoietic cell signatures are shown by colours of
cell population names and dendrograms. Rows are individual
patients. The disease categories are shown by colours on the left
side of the heatmap. This analysis did not aim to classify disease
samples, therefore reasonably, hierarchical clustering of rows did
not classify disease samples. Abbreviations: CFU, colony forming
unit; HSC, haematopoietic stem cell; CMP, common myeloid
progenitor; GMP, granulocyte monocyte progenitor; MEP,
megakaryocyte-erythroid progenitor.
(EPS)
Figure S2 Boxplots showing the distributions of gene signature
score in leukaemic disease samples for indicated haematopoietic
cell populations: (a) Mature B cell class switched; (b) Neutrophilic
metamyelocyte; (c) Granulocyte-monocyte progenitor (GMP); and
(d) Pro B cell. Positive values indicate that samples showed positive
correlations with the corresponding gene signature.
(EPS)
Figure S3 CCAM results of AML patient samples using CMP,
CFU-monocyte, Neutrophilic metamyelocyte, and mature Neu-
Visualisation of Normal and Disease Transcriptomes
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trophils as explanatory variables. (a) All the AML subtypes are
displayed with haematopoietic cell data. (b) Individual disease
subtypes are separately displayed with haematopoietic cell data.
(EPS)
Figure S4 CCAM results of haematopoietic cell population data
explained by major leukaemic phenotypes. CCAM was performed
to analyse 38 hametopoietic cell populations using ‘average’
leukaemic cells (AML, ALL, CML, and CLL) as explanatory
variables. (a) Disease and Cell plot. CCAM result of 38
haematopoietic cell populations (211 samples) is displayed with
the average phenotypes of four major leukaemia subtypes. (b)
Baricentres of haematopoietic cell populations are shown.
Developmental pathways for erythrocyte, megakaryocyte, granu-
locyte, monocyte, and B cell lineages are shown by arrows. (c)
Spider plots of selected cell lineages. The barycentre of each cell
population is connected with individual cell samples, showing the
distributions of each cell population. Dashed arrows show the
developmental pathways of each cell lineage. It is not sound to use
too many explanatory variables in CCAM, as CCAM regresses
main data on explanatory variables, which is one of the major
limitations of this method. Thus, in order to analyse the
differentiation pathways of many normal haematopoietic cell
populations in terms of the features of leukaemias, haematopoietic
cell data has to be treated as main data, using leukaemic data as
explanatory variables (note that this is the opposite way of Fig. 1).
Map analysis indicates that the largest difference was observed
between myeloid and lymphoid lineages (axis 1, a), and the second
largest difference was between ALL and CML (axis 2, a). CCAM
shows that (1) acute leukaemias (AML and ALL) are more
associated with immature haematopoietic stem cells; (2) AML is
more associated with immature myeloid lineage cells including
CMP than differentiated myeloid cells; (3) CML is correlated with
relatively differentiated monocytic and granulocytic lineage cells
(especially, neutrophilic metamyelocyte and CFU-monocyte); (4)
CLL is correlated with naive and mature B cells [31,34]. (b–c).
The results were compatible with and confirm at the transcrip-
tomic level the common understandings on leukaemias and
haematopoietic cell differentiation. Abbreviations: HSC1, Hae-
matopoietic stem cells (CD133z CD34dim); HSC2, Haematopoi-
etic stem cells (CD38{ CD34z); ERY1, Erythroid CD34z
CD71z GlyA{; ERY2, Erythroid CD34{ CD71z GlyA{;
ERY3, Erythroid CD34{ CD71z GlyAz; ERY4, Erythroid
CD34{ CD71lo GlyAz; ERY5, Erythroid CD34{ CD71{
GlyAz; Mat-B1, Mature B cell class able to switch; Mat-B2,
Mature B cell; Mat-B3, Mature B cell class switched; CD4 TCM,
CD4z Central Memory T cell; CD4 TEM, CD4z Effector
Memory T cell; CD8 TCM, CD8z Central Memory T cell; CD8
TEM, CD8z Effector Memory T cell; CD8 TEM RA,
CD8zCD45RAz Effector Memory T cell; m-DC, Myeloid DC;
p-DC, Plasmacytoid DC; NKa1, Mature NK CD56{CD16z
CD3{; NKa2, Mature NK CD56zCD16zCD3{; NKa3,
Mature NK CD56{CD16{CD3{.
(EPS)
Figure S5 Comparison of the proposed method using CCA and
a conventional multivariate analysis, principal component analysis
(PCA). The CCA results are from the analysis in Fig. 3.
(EPS)
Figure S6 Three-dimensional plot of the HSC-CMP score, gene
expression (average expression in each cell population), and four
haematopoietic populations used for making the HSC-CMP score.
CCAM assigned scores to both MDS disease samples and these
genes. High scores were associated with MDS patients with poor
prognosis (c.f. Fig. 4 and 5), while, at the gene level, genes with
high scores showed higher expressions in HSC and MEP than
GMP and CMP. On the other hand, genes with low scores are
more highly expressed in CMP and GMP than HSC and MEP.
See Table S1 for the relative contributions of those four
haematopoietic populations to the HSC-CMP score.
(EPS)
Figure S7 Graphical representation of the proposed method.
Microarray data of undefined cells are standardized and
designated as S, and those of well-characterized cell subsets are
preanalysed by PCA and Canonical Variate Criterion to produce
F. Generally, the number of environmental variable q is much
smaller than that of samples p and genes l, thus the number of new
axes by singular value decomposition (SVD) is q.
(EPS)
Table S1 Excel file of the list of genes that were used for
constructing the HSC-CMP score, the gene scores of the CCAM
result, and the biological/haematological features of these genes.
(XLS)
File S1 R script for CCAM.
(R)
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